Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) EBITDA Margin (2019 - 2025)

Keros Therapeutics' EBITDA Margin history spans 6 years, with the latest figure at 5072.79% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 1555586.0% year-over-year to 5072.79%; the TTM value through Dec 2025 reached 27.66%, down 17566650.0%, while the annual FY2025 figure was 27.69%, N/A changed from the prior year.
  • EBITDA Margin reached 5072.79% in Q4 2025 per KROS's latest filing, down from 107.87% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 1576900.0% in Q1 2021 to a low of 541000.0% in Q3 2023.
  • Average EBITDA Margin over 5 years is 81479.1%, with a median of 176.6% recorded in 2025.
  • Peak YoY movement for EBITDA Margin: tumbled -157703403bps in 2022, then surged 52588222bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 27.18% in 2021, then plummeted by -393bps to 134.03% in 2022, then crashed by -24137bps to 32486.01% in 2023, then soared by 132bps to 10483.07% in 2024, then crashed by -148bps to 5072.79% in 2025.
  • Per Business Quant, the three most recent readings for KROS's EBITDA Margin are 5072.79% (Q4 2025), 107.87% (Q3 2025), and 219.16% (Q2 2025).